• Digital therapeutics (DTx) startup Sidekick Health and pharma giant Pfizer have partnered to launch a digital therapeutic solution targeting treatment adherence for atopic dermatitis also commonly known as eczema. The two companies previously worked together in 2020 to launch a digital medication management and lifestyle platform across Europe. 

<ul><li>The DTx will target patient adherence to treatment of the skin disease via gamification and behavioral changes. Additionally, an AI algorithm customizes treatments for patients. The therapeutic will initially be launched in the UK and then rolled out in Europe (Belgium, Norway, the Netherlands, Sweden, France), Ireland, and Japan later this year. The launch follows Sidekick’s USD 55 million funding round earlier this month.</ul>

• The firm reported a feasibility study of the DTx that demonstrated medication adherence improvement in 83% of users with chronic conditions. An independent study also showed an almost 50% reduction in the overall severity of symptoms. 

• Iceland-based Sidekick Health is focused on developing personalized programs for patients with chronic conditions, offering gamified content that incorporates lifestyle changes and clinical treatments to improve healthcare outcomes. The firm partners with health plans such as Anthem to reach patients and has previously worked with companies such as Pfizer and Bayer to develop DTx solutions, serving patients across multiple countries.